A Guide to Use of Antibiotics in Patients with Renal Disease
Authors: CALVIN M. KUNIN
Journal: Annals of Internal Medicine (1967)

Diagnosis and Treatment1 July 1967A Guide to Use of Antibiotics in Patients with Renal DiseaseA Table of Recommended Doses and Factors Governing Serum LevelsCALVIN M. KUNIN, M.D., F.A.C.P.CALVIN M. KUNIN, M.D., F.A.C.P.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-67-1-151 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe complexity of antimicrobial therapy has increased as new drugs and the analogues of older agents have grown in number. Clinical practice has also been complicated by the necessity to use potentially toxic drugs in patients with diseases of the liver or the kidney, or both. Numerous reports are available in the literature concerning the alteration of the fate of antimicrobial agents in the presence of disease of these organs, but they are not always readily available when the information is required for immediate therapeutic decisions.This report contains a compilation of the currently available data on factors that determine...References General Penicillins Cephalosporins Erythromycin Lincomycin Novobiocin Tetracyclines Chloramphenicol Kanamycin, Neomycin, and Gentamicin Streptomycin Vancomycin Ristocetin Polymyxin and Colistin Bacitracin Nitrofurantoin Isoniazid, Pas, and Cycloserine Amphotericin B1. BULGERBENNETTBOEN RJJVST: Intraperitoneal administration of broad-spectrum antibiotics in patients with renal failure. JAMA 194: 1198, 1965. CrossrefMedlineGoogle Scholar2. GOMBOSKATZFEDORKOALLNOCHLEE EASJHTH: Dialysis properties of newer antimicrobial agents. Antimicrob. Agents Chemother. 4: 373, 1964. Google Scholar3. GREENBERGSANFORD PAJP: Removal and absorption of antibiotics in patients with renal failure undergoing peritoneal dialysis. Ann. Intern. Med. 66: 465, 1967. LinkGoogle Scholar4. KUNINFINLAND CMM: Restrictions imposed on antibiotic therapy by renal failure. Arch. Intern. Med. (Chicago) 104: 1030, 1959. CrossrefMedlineGoogle Scholar5. SHEARSHINABERGERBARRY LJHKG: Peritoneal transport of antibiotics in man. New Eng. J. Med. 272: 666, 1965. CrossrefMedlineGoogle Scholar6. YAFFE SJ: Antibiotic dosage in new born and premature infants. JAMA 193: 818, 1965. CrossrefMedlineGoogle Scholar7. ZINNEMANHALLHONGSEAL HHWHLUS: Binding of erythromycin, novobiocin, chloramphenicol, chlortetracycline, and nitrofurantoin by serum proteins. Antimicrob. Agents Chemother. p. 637, 1962. Google Scholar8. BULGERLINDHOLMMURRAYKIRBY RJDDJSWM: Effect of uremia on methicillin and oxacillin blood levels. JAMA 187: 319, 1964. CrossrefMedlineGoogle Scholar9. EAGLENEWMAN HE: The renal clearance of penicillins F, G, K, and X in rabbits and man. J. Clin. Invest. 26: 903, 1947. CrossrefGoogle Scholar10. GRATTAN WA: Hematuria and azotemia associated with administration of methicillin. J. Pediat. 64: 285, 1964. CrossrefMedlineGoogle Scholar11. KUNINFINLAND CMM: Persistence of antibiotics in blood of patients with acute renal failure. III. Penicillin, streptomycin, erythromycin and kanamycin. J. Clin. Invest. 38: 1509, 1959. CrossrefMedlineGoogle Scholar12. NEWWELLS PSCE: Cerebral toxicity associated with massive intravenous penicillin therapy. Neurology (Minneap.) 15: 1053, 1965. CrossrefMedlineGoogle Scholar13. SCHRIERBULGERVANARSDEL RWRJPP: Nephropathy associated with penicillin and homologues. Ann. Intern. Med. 64: 116, 1966. LinkGoogle Scholar14. WEINSTEINLERNERCHEW LPIWH: Clinical and bacteriologic studies of the effect of "massive" doses of penicillin G on infections caused by gram-negative bacilli. New Eng. J. Med. 271: 525, 1964. CrossrefMedlineGoogle Scholar15. GRIFFITHBLACK RSHR: Cephalothin—a new antibiotic. Preliminary clinical and laboratory studies. JAMA 189: 823, 1964. CrossrefMedlineGoogle Scholar16. KABINSCOHEN SAS: Cephalothin serum levels in the azotemic patient. Antimicrob. Agents Chemother. 4: 207, 1964. Google Scholar17. KABINSCOHEN SAS: Cephaloridine therapy as related to renal function. Antimicrob. Agents Chemother. p. 922, 1965. MedlineGoogle Scholar18. KUNINATUK CMN: Excretion of cephaloridine and cephalothin in patients with renal impairment. New Eng. J. Med. 274: 654, 1966. CrossrefMedlineGoogle Scholar19. LEEHERRANDERSON CCEBRC: Pharmacological and toxicological studies on cephalothin. Clin. Med. 70: 1123, 1963. Google Scholar20. STEWARTHOLT GTRJ: Laboratory and clinical results with cephaloridine. Lancet 2: 1305, 1964. CrossrefMedlineGoogle Scholar21. WELLESGIBSONHARRISSMALLANDERSON JSWRPNRMRC: Toxicity, distribution, and excretion of cephaloridine in laboratory animals. Antimicrob. Agents Chemother. 5: 863, 1965. MedlineGoogle Scholar22. GRIFFITHJOHNSTONESMITH RSDMJW: The distribution and excretion of erythromycin following intravenous injection. Antibiot. Ann. p. 496, 1953-1954. Google Scholar23. LEEANDERSONCHEN CCRCKK: Renal clearance of erythromycin. Proc. Soc. Exp. Biol. Med. 88: 584, 1955. CrossrefMedlineGoogle Scholar24. BAKERSOKOLSKIYEAGER RHWTRL: Unpublished protein-binding data. Google Scholar25. EBERTSSOKOLSKIWAGNER FSWRJG: Unpublished renal clearance data. Google Scholar26. MALIMNODINE PMJH: Human pharmacological studies of lincomycin, a new antibiotic for gram-positive organisms. Antimicrob. Agents Chemother. p. 183, 1963. MedlineGoogle Scholar27. MEDINAFISKEHYELT-JARVYBROWNPRIGOT ANICDA: Absorption, diffusion, and excretion of a new antibiotic, lincomycin. Ibid., p. 189. Google Scholar28. REINARZMCINTOSH JADA: Lincomycin excretion in patients with normal renal function, severe azotemia, and with hemodialysis and peritoneal dialysis. Antimicrob. Agents Chemother. 5: 232, 1965. MedlineGoogle Scholar29. VAVRASOKOLSKILAWSON JJWTJB: Absorption and excretion of lincomycin in hydrochloride in human volunteers. Antimicrob. Agents Chemother. p. 176, 1963. MedlineGoogle Scholar30. FINLANDNICHOLS MRL: Novobiocin. Antibiot. Chemother. (Basel) 4: 209, 1957. CrossrefMedlineGoogle Scholar31. SIMONMCCUNEDINEENROGERS HJRMPADA: Studies on novobiocin, a new antimicrobial agent. Antibiot. Med. Clin. Ther. 2: 205, 1956. MedlineGoogle Scholar32. WRIGHTPUTNAMWELCH WWLEH: Novobiocin: serum concentrations and urinary excretion following oral administration in man. Ibid., p. 311. Google Scholar33. BATEMANBARBERIOGRICEPIERPONT JCJPKH: Fatal complications of intensive antibiotic therapy in patients with neoplastic disease. Arch. Intern. Med. (Chicago) 90: 763, 1952. CrossrefGoogle Scholar34. BENNETTMICKELWAITBARRETTBRODIEKIRBY JVJSJEJLWM: Comparative serum binding of four tetracyclines under simulated in vivo conditions. Antimicrob. Agents Chemother. 5: 180, 1965. MedlineGoogle Scholar35. CHULSKIJOHNSONSCHLAGELWAGNER TRHCAJG: Direct proportionality of urinary excretion rate and serum level of tetracycline in human subjects. Nature (London) 198: 450, 1963. CrossrefMedlineGoogle Scholar36. FALOONNOLLPRIOR WWJWJT: Nitrogen metabolism and liver histology during aureomycin administration in patients with hepatic disease. J. Lab. Clin. Med. 41: 596, 1953. MedlineGoogle Scholar37. GABUZDAGOCKEJACKSONGIRGSBYLOVEFINLAND GJTMGGMDBCM: Some effects of antibiotics on nutrition in man. Arch. Intern. Med. (Chicago) 101: 476, 1958. CrossrefGoogle Scholar38. KUNINDORNBUSHFINLAND CMACM: Distribution and excretion of four tetracycline analogues in normal young men. J. Clin. Invest. 38: 1950, 1959. CrossrefMedlineGoogle Scholar39. SHILS ME: Chlortetracycline therapy with renal disease. New Eng. J. Med. 275: 113, 1966. CrossrefGoogle Scholar40. SHILS ME: Renal disease and the metabolic effects of tetracycline. Ann. Intern. Med. 58: 389, 1963. LinkGoogle Scholar41. SIROTASALTZMAN JHA: The renal clearance and plasma protein binding of aureomycin in man. J. Pharmacol. Exp. Ther. 100: 210, 1950. MedlineGoogle Scholar42. GLAZKOWOLFDILLBRATTON AJLMWAAC: Biochemical studies on chloramphenicol (Chloromycetin). II. Tissue distribution and excretion studies. J. Pharmacol. Exp. Ther. 96: 445, 1949. MedlineGoogle Scholar43. KUNINGLAZKOFINLAND CMAJM: Persistence of antibiotics in blood of patients with acute renal failure. II. Chloramphenicol and its metabolic products in the blood of patients with severe renal disease or hepatic cirrhosis. J. Clin. Invest. 38: 1498, 1959. CrossrefMedlineGoogle Scholar44. LAMBDINWADDELLBIRDSONG MAWWM: Chloramphenicol toxicity in the premature infant. Pediatrics 25: 935, 1960. MedlineGoogle Scholar45. LISCHNERSELIGMANKRAMMERPARMELEE HSJAAH: An outbreak of neonatal deaths among term infants associated with administration of chloramphenicol. J. Pediat. 59: 21, 1961. CrossrefMedlineGoogle Scholar46. MCCURDY PR: Plasma concentration of chloramphenicol and bone marrow suppression. Blood 21: 363, 1963. CrossrefGoogle Scholar47. SUHRLANDWEISBERGER LGAS: Chloramphenicol toxicity in liver and renal disease. Arch. Intern. Med. (Chicago) 112: 747, 1963. CrossrefMedlineGoogle Scholar48. SUTHERLAND JM: Fatal cardiovascular collapse of infants receiving large amounts of chloramphenicol. J. Dis. Child. 97: 761, 1959. MedlineGoogle Scholar49. WEISSGLAZKOWESTON CFAJJK: Chloramphenicol in the newborn infant. A physiologic explanation of its toxicity when given in excessive doses. New Eng. J. Med. 262: 787, 1960. CrossrefMedlineGoogle Scholar50. ATUKMOSCAKUNIN NOACM: The use of potentially nephrotoxic antibiotics in the treatment of gram-negative infections in uremic patients. Ann. Intern. Med. 60: 28, 1964. LinkGoogle Scholar51. BATESSCHULTZABERNATHY THTCRS: Kanamycin administration in patients with impaired renal function (abstract). Southern Soc. Clin. Res. 13: 77, 1965. Google Scholar52. BERNERBERGSTOMWEHRLE SHWHPF: Renal clearance of kanamycin in children. Antibiot. Ann. p. 684, 1958-1959. MedlineGoogle Scholar53. BLACKCALESNICKWILLIAMSWEINSTEIN JBDMJ: Pharmacology of gentamicin, a new broad-spectrum antibiotic. Antimicrob. Agents Chemother. p. 138, 1963. MedlineGoogle Scholar54. BOGERGAVIN WPJJ: Kanamycin: its cerebrospinal fluid diffusion renal clearance, and comparison with streptomycin. Antibiot. Ann. p. 667, 1958-1959. Google Scholar55. BULGERSIDELLKIRBY RJSWM: Laboratory and clinical studies of gentamicin, a new broad-spectrum antibiotic. Ann. Intern. Med. 59: 593, 1963. LinkGoogle Scholar56. EINSPRUCHGONZALEZ BCVV: Clinical and experimental nephropathy resulting from use of neomycin sulfate. JAMA 173: 809, 1960. CrossrefMedlineGoogle Scholar57. FINEGOLD SM: Kanamycin. Arch. Intern. Med. (Chicago) 104: 15, 1959. CrossrefGoogle Scholar58. JAOJACKSON RLGG: Gentamicin sulfate, new antibiotic against gram-negative bacilli. Laboratory, pharmacological, and clinical evaluation. JAMA 189: 817, 1964. CrossrefMedlineGoogle Scholar59. KUNINCHALMERSLEEVYSEBASTYENLIEBERFINLAND CMTCCMSCCSM: Absorption of orally administered neomycin and kanamycin with special reference to patients with severe hepatic and renal disease. New Eng. J. Med. 262: 380, 1960. CrossrefMedlineGoogle Scholar60. LASTSHERLOCK PMS: Systemic absorption of orally administered neomycin in liver disease. Ibid., p. 385. Google Scholar61. ORYWILLIAMSCAMPREGESTERMORGEN EMRWFARFRO: Kanamycin in the treatment of patients with diminished kidney function. Ann. N. Y. Acad. Sci. 132: 933, 1966. CrossrefMedlineGoogle Scholar62. QUINNMCHENRYTRUANTCOX ELMDJPF: The use of kanamycin in selected patients with serious infections caused by gram-negative bacilli: serum concentration and inhibition studies in patients with azotemia given reduced doses. Ibid., p. 850. Google Scholar63. TISCHHUGTALENDICKISON DEJBHL: Pharmacological studies with kanamycin. Ann. N. Y. Acad. Sci. 76: 44, 1958. CrossrefMedlineGoogle Scholar64. WELCHWRIGHTWEINSTEINSTAFFA HWWHIAW: In vitro and pharmacological studies with kanamycin. Ibid., p. 66. Google Scholar65. ADCOCKHETTIG JDRA: Absorption, distribution, and excretion of streptomycin. Arch. Intern. Med. (Chicago) 77: 179, 1946. CrossrefGoogle Scholar66. BOXERJELINEKEDISON GEVCAO: Streptomycin: clearance and binding to protein. J. Pharmacol. Exp. Ther. 97: 93, 1949. MedlineGoogle Scholar67. EDWARDSWHYTE KDHM: Streptomycin poisoning in renal failure: an indication for treatment with an artificial kidney. Brit. Med. J. 1: 752, 1959. CrossrefMedlineGoogle Scholar68. RAKEDONOVICK GR: Absorption, distribution and excretion of streptomycin, in Streptomycin, Its Nature and Practical Application, edited by WAKSMAN, S. A. The Williams & Wilkins Co., Baltimore, 1949, chap. 14. Google Scholar69. ZINTELFLIPPINNICHOLSWILEYRHOADS NAHFACMMJE: Studies on streptomycin in man. I. Absorption, distribution, excretion and toxicity. Amer. J. Med. Sci. 210: 421, 1945. CrossrefGoogle Scholar70. GERACIHEILMANNICHOLSWELLMANROSS JEFRDRWEGT: Some laboratory and clinical experiences with a new antibiotic, vancomycin. Antibiot. Ann. p. 90, 1956-1957. MedlineGoogle Scholar71. KIRBYDIVELBISS WMCL: Vancomycin: clinical and laboratory studies. Ibid., p. 107. Google Scholar72. LEEANDERSONCHEN CCRCMK: Vancomycin, a new antibiotic. V. Distribution, excretion and renal clearance. Ibid., p. 82. Google Scholar73. LINDHOLMMURRAY DDJS: Persistence of vancomycin in the blood during renal failure and its treatment by hemodialysis. New Eng. J. Med. 274: 1047, 1966. CrossrefMedlineGoogle Scholar74. BILLOWMARTORELLALUPINIPALEY BWFJBSS: Clinical observations on ristocetin: a preliminary report on its efficacy and toxicity in 20 unselected severe respiratory infections. Antibiot. Ann. p. 447, 1958-1959. MedlineGoogle Scholar75. GANGAROSALANDERMANROSCHHERNDON EJNSPJEG: Hematologic complications arising during ristocetin therapy: relation between dose and toxicity. New Eng. J. Med. 259: 156. 1958. CrossrefMedlineGoogle Scholar76. BOGERGAVIN WPJJ: Absorption, excretion, and distribution of colistin. Antimicrob. Agents Chemother. p. 429, 1961. Google Scholar77. FEKETYNORMANCLUFF FRPSLE: The treatment of gram-negative bacillary infections with colistin. The toxicity and efficacy of large doses in forty-eight patients. Ann. Intern. Med. 57: 214, 1962. LinkGoogle Scholar78. HOPPERJAWETZHINMAN JEF: Polymyxin B in chronic pyelonephritis: observations on the safety of the drug and on its influence on the renal infection. Amer. J. Med. Sci. 225: 402, 1953. CrossrefMedlineGoogle Scholar79. MACKAYKAYE DND: Serum concentrations of colistin in patients with normal and impaired renal function. New Eng. J. Med. 270: 394, 1964. CrossrefMedlineGoogle Scholar80. NORDHOEPRICH NMPD: Polymyxin B and colistin. A critical comparison. Ibid., p. 1030. Google Scholar81. PARKERHOEPRICH RHPD: Toxicity associated with intravenous and intramuscular polymyxin B sulfate (abstract). Clin. Res. 12: 244, 1964. Google Scholar82. PERKINS RL: Apnea with intramuscular colistin therapy. JAMA 190: 421, 1964. CrossrefMedlineGoogle Scholar83. PULASKIBAKERROSENBERGCONNELL EJHJMLJF: Laboratory and clinical studies of polymyxin B and E. J. Clin. Invest. 28: 1028, 1949. CrossrefGoogle Scholar84. WRIGHTWELCH WWH: Chemical, biological and clinical observations on colistin. Antibiot. Ann. 7: 61, 1959-1960. MedlineGoogle Scholar85. YOWMOYER EMJH: Toxicity of polymyxin B. Arch. Intern. Med. (Chicago) 92: 248, 1953. CrossrefGoogle Scholar86. EAGLENEWMANGRIEIFBURKHOLDERGOODMAN HEVRTMSC: The blood levels and renal clearance in rabbits and man of an antibiotic derived from B. subtilis (bacitracin). J. Clin. Invest. 26: 919, 1947. CrossrefGoogle Scholar87. ZINTELMANICHOLSELLIS HARAACH: The absorption, distribution, excretion and toxicity of bacitracin in man. Amer. J. Med. Sci. 218: 439, 1949. CrossrefMedlineGoogle Scholar88. BUZARDBENDERNOHLEHUMPHREYPAUL JARCEGDTMF: Renal tubular transport of nitrofurantoin. Amer. J. Physiol. 202: 1136, 1962. CrossrefMedlineGoogle Scholar89. HALLIDAYJAWETZ AE: Intravenous sodium nitrofurantoin: a limited study. Antimicrob. Agents Chemother. p. 317, 1961. Google Scholar90. PAULBENDERNOHLE MFRCEG: Renal excretion of nitrofurantoin (furadantin). Amer. J. Physiol. 197: 580, 1959. CrossrefMedlineGoogle Scholar91. RECKENDORFCASTRINGIUSSPINGLER HKRGHK: Comparative pharmacodynamics, urinary excretion, and half-life determination of nitrofurantoin sodium. Antimicrob. Agents Chemother. p. 531, 1962. Google Scholar92. SCHIRMEISTERSTEFANIWILLMANNHALLAUER JFHW: Renal handling of nitro-furantoin in man. Antimicrob. Agents Chemother. 5: 223, 1965. MedlineGoogle Scholar93. WOODRUFFMALVINTHOMPSON MWRLIM: The renal transport of nitrofurantoin. Effect of acid balance upon its excretion. JAMA 175: 1132, 1961. CrossrefMedlineGoogle Scholar94. DESPREZBOONE RIU: Metabolism of C14 isoniazid in humans. Amer. Rev. Resp. Dis. 84: 42, 1961. MedlineGoogle Scholar95. ELMENDORFCAWTHONMUSCHENHEINMCDERMOTT DFWUCW: The absorption, distribution, excretion, and short-term toxicity of isonicotinic acid hydrozide (Nydrazid) in man. Amer. Rev. Resp. Dis. 65: 429, 1952. Google Scholar96. JENNEMACDONALDMENDOZA JWFME: A study of the renal clearances, metabolic inactivation rates, and serum fall-off interaction of isoniazid and paraaminosalicylic acid in man. Amer. Rev. Resp. Dis. 84: 371, 1961. MedlineGoogle Scholar97. JENNE JW: Partal purification and properties of the isoniazid transacetylase in human liver. Its relationship to the acetylation of p-amino-salicylic acid. J. Clin. Invest. 44: 1192, 1965. CrossrefGoogle Scholar98. NAIREPSTEINBARONMULINOS KGIGHMG: Absorption, distribution, and excretion of cycloserine in man. Antibiot. Ann. p. 136, 1955-1956. MedlineGoogle Scholar99. STOREYCUVALLMCLEAN PBRCRL: The convulsive effect of cycloserine. Antibiot. Med. Clin. Ther. 3: 258, 1956. MedlineGoogle Scholar100. WELCHPUTNAMRANDALL HLDWA: Antibacterial activity and blood and urine concentrations of cycloserine, a new antibiotic, following oral administration. Antibiot. Med. Clin. Ther. 1: 72, 1955. MedlineGoogle Scholar101. ANDRIOLEKRAVETZ VTHM: The use of amphotericin B in man. JAMA 180: 269, 1962. CrossrefMedlineGoogle Scholar102. BELLANDRIOLESABESINUTZ NHVTSMJP: On the nephrotoxicity of amphotericin B in man. Amer. J. Med. 33: 64, 1962. CrossrefMedlineGoogle Scholar103. BUTLERBENNETTALLINGWERTLAKEUTZHILL WTJEDWPTJPGJ: Nephrotoxicity of amphotericin B; early and late effects in 81 patients. Ann. Intern. Med. 61: 175, 1964. LinkGoogle Scholar104. BUTLERHILLSZWEDKNIGHT WTGJCFV: Amphotericin B renal toxicity in the dog. J. Pharmacol. Exp. Ther. 143: 47, 1964. MedlineGoogle Scholar105. LOURIA DB: Some aspects of the absorption, distribution, and excretion of amphotericin B in man. Antibiot. Med. Clin. Ther. (Amer.) 5: 295, 1958. MedlineGoogle Scholar106. RHOADES E: Effect of amphotericin B upon renal function in man (abstract). Clin. Res. 8: 232, 1960. Google Scholar107. VOGELCRUTCHER RAJC: Studies on the bioassay and excretion of amphotericin B in patients with systemic mycoses. Antibiot. Med. Clin. Ther. (Amer.) 5: 501, 1958. MedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Charlottesville, VirginiaFrom the Departments of Preventive Medicine and Medicine, University of Virginia School of Medicine, Charlottesville, Va.Requests for reprints should be addressed to Calvin M. Kunin, M.D., Department of Preventive Medicine, University of Virginia School of Medicine, Charlottesville, Va. 22901. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAntibiotic TherapyArzneimitteltherapie bei Patienten mit NiereninsuffizienzDosierung von Antiinfektiva bei Nierenversagen und Nierenersatztherapie in der IntensivmedizinPragmatic Use of Kidney Function Estimates for Drug Dosing: The Tide Is TurningDrug Metabolism in Kidney DiseaseSuboptimal antimicrobial drug exposure in patients with renal impairmentA Synopsis of Clinical Pharmacokinetic Alterations in Advanced CKDDosierung von Antibiotika bei Nierenfunktionsstörung und kontinuierlicher NierenersatztherapiePharmakodynamik und Pharmakokinetik beim Intensivpatienten, InteraktionenPharmakodynamik und Pharmakokinetik beim Intensivpatienten, InteraktionenTetracyclines, Glycylcyclines, and ChloramphenicolMacrolides, Clindamycin, and KetolidesArzneimitteltherapie bei Patienten mit NiereninsuffizienzDrug Kinetics, Dosing, and Renal Toxicity in Older AdultsEarly Research on Renal Function and Drug ActionPharmakodynamik und Pharmakokinetik beim Intensivpatienten, InteraktionenOn Warfarin Use in Kidney Disease: A Therapeutic Window of Opportunity?Cephalothin and CefazolinNovobiocinUmfrage zur Arzneimitteldosierung bei Niereninsuffizienz unter nephrologisch tätigen ÄrztenReview on Pharmacokinetics and Pharmacodynamics and the Aging KidneyTetracyclines and ChloramphenicolMacrolides, Clindamycin, and KetolidesDrug Therapy in Patients With Chronic Renal FailureTetracycline-induced renal failure after dental treatmentPolymyxins RevisitedPharmakodynamik und Pharmakokinetik beim Intensivpatienten, InteraktionenNephrotoxische Störungen und nierenabhängige ArzneimittelPharmakotherapieTherapeuticsAntimykotika unter kontinuierlicher Nierenersatztherapie. Antimycotic drugs under continuous renal replacement therapyPharmakotherapie bei eingeschr�nkter NierenfunktionEvaluation of colistin as an agent against multi-resistant Gram-negative bacteriaAsymptomatic Bacteriuria in Elderly PatientsDosierungsanpassung bei NiereninsuffizienzPregnancy and Renal FailureSafety and Tolerability of Bolus Intravenous Colistin in Acute Respiratory Exacerbations in Adults with Cystic FibrosisInduced Expression of Sarcotoxin IA Enhanced Host Resistance Against Both Bacterial and Fungal Pathogens in Transgenic TobaccoA Concept for Pharmacokinetic- Pharmacodynamic Dosage Adjustment in Renal ImpairmentDosierungsanpassung bei NiereninsuffizienzPolymyxin B Sulfate and Colistin: Old Antibiotics for Emerging Multiresistant Gram-Negative BacteriaStandardized structure and modular design of a pharmacokinetic databaseSustained-release microcapsules of nitrofurantoin and amoxicillin; preparation, in-vitro release rate, kinetic and micromeritic studiesIn vivo/in vitro correlations of nitrofurantoin matrix tablet formulationsSustained-release dosage form of nitrofurantoin. Part 1. Preparation of microcapsules and in vitro release kineticsErythromycin-Induced Hypoacusis: 11 New Cases and Literature ReviewDrug handling in renal impairmentRenal disease in the elderlyThe Impact of Renal Dysfunction on Drug Handling and How to Compensate for ItMode of Action, Biotransformation and Pharmacokinetics of Antituberculosis Drugs in Animals and ManErythromycin: A Microbial and Clinical Perspective After 30 Years of Clinical Use (First of Two Parts)Pharmacokinetics and metabolism of rosaramicin in humansThe use of antibiotics in reptiles: a reviewChloramphenicol toxicity in neonates: its incidence and prevention.Pharmacokinetics in Renal FailureAntimicrobial chemotherapy in the dog.Drugs and the KidneyDosage regimen designCefoperazone treatment of experimental endocarditisRenal diseasePharmacokinetics of cefmetazole in normal subjects and in patients with impaired renal functionDisposition kinetics of disopyramide in patients with renal insufficiencyGrundlagen der PharmakokinetikChemotherapy with Antibacterial AgentsThe Pathology of Nephrotoxicity of Gentamicin in SnakesAmikacin Serum Concentrations: Prediction of Levels and Dosage GuidelinesFELIX A. SARUBBI Jr., M.D., J. HEYWARD HULL, M.S.The AminoglycosidesAntibacterial Therapy in Renal and Hepatic DiseaseTreatment of Experimental Staphylococcus aureus Endocarditis: Comparison of Cephalothin, Cefazolin, and MethicillinChemically Defined Antimicrobial Susceptibility Test Medium for Pseudomonas aeruginosaIntensivtherapieInfluence of nutritional status on plasma levels and relative bioavailability of tetracyclineProphylaxe und Therapie der Shuntthrombose bei terminaler NiereninsuffizienzPharmakokinetics of ErythromycinDrug Metabolism under Pathological and Abnormal Physiological States in Animals and ManSensitivity of Brucella spp to tetracycline and its analogues.Symposium on Doxycycline: Held in Brussels, April 2–3, 1976Acute Renal FailureQuantitation of Antibiotics Using High-Pressure Liquid Chromatography: TetracyclineDrug ExcretionNitrofurantoinCritical compilation of terminal half-lives, percent excreted unchanged, and changes of half-life in renal and hepatic dysfunction for studies in humans with referencesPharmacokinetic Data and Drug Monitoring: I. Antibiotics and AntiarrhythmicsPharmacokinetics of Creatinine in Man and Its Implications in the Monitoring of Renal Function and in Dosage Regimen Modifications in Patients with Renal InsufficiencyAbsorption, Distribution, Excretion, and Response to the Drug in the Presence of Chronic Renal FailureForensische ToxikologieClinical Features in Shock Associated with Gram-Negative BacteremiaRenal function and the rate of disappearance of methotrexate from serumIndividualization of Drug Dosage in Patients with Renal DiseaseAntimicrobial Drug Therapy in Pediatric PracticeTetracycline hepatotoxicity in the differential diagnosis of postoperative jaundiceβ-Lactam-Antibiotica (Penicilline (P), Cephalosporine (C))Urinary Tract InfectionDrug Selection and Dosage in Renal InsufficiencyIn Patients with Renal and Hepatic Insufficiency: Part III the AminoglycosidesTranslation of pharmacokinetics to clinical medicineThe Effect of Doxycycline on Renal Function in Patients with Advanced Renal InsufficiencyRenal excretion of sulfadimidine in normal and uremic subjectsIsoniazid Dosage in Patients with Renal FailureSerum Protein Binding of Erythromycin, Lincomycin, and ClindamycinAntibiotics and the KidneyCephalexin Concentrations in Sputum During Acute Respiratory InfectionsA Review of the Clinical Use of Antimicrobial Agents in Patients with Renal and/or Hepatic Insufficiency II. the CephalosporinsProtein Binding of Drugs in Plasma from Patients with Acute Renal FailureA Review of the Clinical Use of Antimicrobial Agents in Patients with Renal and Hepatic Insufficiency I. the PenicillinsAntimikrobielle ChemotherapieComplications of colonic and rectal surgery: Results of a study of early presumptive antimicrobial therapy of serious infections in surgical patients with intestinal diseasesTobramycin and Gentamicin Concentrations in the Serum of Normal and Anephric PatientsModelling of individual pharmacokinetics for computer-aided drug dosageRENAL EXCRETION OF SULPHADIMIDINE IN NORMAL AND URÆMIC SUBJECTSVariable Drug Responses in ManDialysis as a substitute for renal function in surgical patientsTranslation of Pharmacokinetics to Clinical MedicineDiagnosis and Treatment of Urinary Tract InfectionsUrinary Tract InfectionsSelection and Preparation of Patients for Renal TransplantationClostridium welchii septicotoxemiaInfectious Complications of Neoplastic DiseaseMultiple Dose Kinetics and Drug Dosage in Patients with Kidney DiseaseExtracorporeal and Peritoneal Dialysis of DrugsThe Conservative Management of Acute Oliguric Renal FailureConservative Management of Chronic Renal FailureDepression of cardiac function by streptomycin and other antimicrobial agentsRecovery from Colistimethate NephrotoxicityRUSSELL E. RANDALL JR., M.D., F.A.C.P., GEORGE S. BRIDI, M.D., JOHN G. SETTER, M.D., NEWTON C. BRACKETT JR., M.D.Methicillin: Critical Appraisal after a Decade of ExperienceThe TetracyclinesThe Cephalosporins Microbiological, Chemical, and Pharmacological Properties and Use in Chemotherapy of InfectionLOUIS WEINSTEIN, Ph.D., M.D., F.A.C.P., KENNETH KAPLAN, M.D.Die konservative Intensivbehandlung beim akuten NierenversagenDosierungsanpassung bei NiereninsuffizienzCephalexin: human studies of absorption and excretion of a new cephalosporin antibioticAntimicrobial agentsCurrent Concepts in the Pathogenesis and Management of Acute Renal FailureRate of drug metabolism in obese volunteers before and during starvation and in azotemic patientsEmergency Treatment of Severe Bacterial InfectionThe Renal Excretion of Nitrogen Containing MetabolitesRENAL CLEARANCE OF SODIUM SULPHADIMIDINE IN NORMAL AND URÆMIC SUBJECTSHost Determinants of Response to Antimicrobial AgentsManagement of postoperative acute renal failureMore on Antimicrobials in Renal FailureCALVIN M. KUNIN, M.D.Effect of Renal Function on Urinary Recovery of Orally Administered NitrofurantoinMedical management of chronic renal failurePeritoneal Dialysis: Indications and Technique in the Surgical PatientCHLORTETRACYCLINE IN UREMIAENRIQUE ROMERO, M.D.WAGES OF ADDICTIONANTIBIOTICS IN RENAL FAILURE 1 July 1967Volume 67, Issue 1Page: 151-158KeywordsAntibioticsAntimicrobialsDrug therapyDrugsLiver diseasesPreventive medicineRenal diseases Issue Published: 1 July 1967 PDF downloadLoading ...